AHA/ASA Guideline

2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment

A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.

Endorsed by the American Association of Neurological Surgeons (AANS); Congress of Neurological Surgeons (CNS); AANS/CNS Cerebrovascular Section; American Society of Neuroradiology; and Society of Vascular and Interventional Neurology

William J. Powers, MD, FAHA, Chair; Colin P. Derdeyn, MD, FAHA, Vice Chair; José Biller, MD, FAHA; Christopher S. Coffey, PhD; Brian L. Hoh, MD, FAHA; Edward C. Jauch, MD, MS, FAHA; Karen C. Johnston, MD, MSc; S. Claiborne Johnston, MD, PhD, FAHA; Alexander A. Khalessi, MD, MS, FAHA; Chelsea S. Kidwell, MD, FAHA; James F. Meschia, MD, FAHA; Bruce Ovbiagele, MD, MSc, MAS, FAHA; Dileep R. Yavagal, MD, MBBS; on behalf of the American Heart Association Stroke Council
Abstract

Purpose—The aim of this guideline is to provide a focused update of the current recommendations for the endovascular treatment of acute ischemic stroke. Where there is overlap, the recommendations made here supersede those of previous guidelines.

Methods—This focused update analyzes results from 8 randomized clinical trials of endovascular treatment and other relevant data published since 2013. It is not intended to be a complete literature review from the date of the previous guideline publication but rather to include pivotal new evidence that justifies changes in current recommendations. Members of the writing committee were appointed by the American Heart Association/American Stroke Association Stroke Council’s Scientific Statement Oversight Committee and the American Heart Association/American Stroke Association Manuscript Oversight Committee (MOC). Strict adherence to the American Heart Association conflict of interest policy was maintained throughout the consensus process. Recommendations follow the American Heart Association/American Stroke Association methods of classifying the level of certainty of the treatment effect and the class of evidence. Prerelease review of the draft guideline was performed by 6 expert peer reviewers and by the members of the Stroke Council Scientific Statement Oversight Committee and Stroke Council Leadership Committee.

Results—Evidence-based guidelines are presented for the selection of patients with acute ischemic stroke for endovascular treatment, the endovascular procedure and for systems of care to facilitate endovascular treatment.
Conclusions—Certain endovascular procedures have been demonstrated to provide clinical benefit in selected patients with acute ischemic stroke. Systems of care should be organized to facilitate the delivery of this care.

Key Words: AHA Scientific Statements; stroke treatment; endovascular stroke treatment; intra-arterial stroke treatment; neurointerventional stroke treatment; stent retriever; ischemic stroke
INTRODUCTION

Since the publication of the most recent “Guidelines for the Early Management of Patients With Acute Ischemic Stroke” in 2013,¹ substantial new high-quality evidence regarding the clinical efficacy of endovascular treatments of acute ischemic stroke has become available. This focused update on endovascular treatment of acute ischemic stroke analyzes results from 8 randomized clinical trials of endovascular treatment and other relevant data published since 2013, while taking into account the previous evidence summarized in the 2013 guidelines. This focused update is not intended to be based on a complete literature review from the date of the previous guideline publication but rather to include pivotal new evidence that justifies changes in current recommendations. Where there is overlap, the recommendations made here supersede those of previous guidelines.

Members of the writing committee were appointed by the American Heart Association/American Stroke Association (AHA/ASA) Stroke Council’s Scientific Statement Oversight Committee and the AHA/ASA Manuscript Oversight Committee, representing various areas of medical expertise. Strict adherence to the AHA conflict of interest policy was maintained throughout the consensus process. Panel members were assigned topics relevant to their areas of expertise, reviewed the stroke literature with emphasis on publications since the prior guidelines, and drafted recommendations in accordance with the American College of Cardiology/AHA’s Level of Evidence grading algorithm (Table 1). All recommendations were unanimously approved by the members of the writing group.
TREATMENT WITH INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR

Rapid administration of intravenous recombinant tissue-type plasminogen activator (r-tPA) to appropriate patients remains the mainstay of early treatment of acute ischemic stroke.\(^1\) Timely restoration of blood flow in ischemic stroke patients is effective in reducing long term morbidity. For patients who meet national and international eligibility guidelines, intravenous r-tPA administration improves functional outcomes at 3 to 6 months when given within 4.5 hours of ischemic stroke onset and should be administered. Every effort should be made to shorten any delays in initiation of treatment as earlier treatments are associated with increased benefits. If patients who are eligible for intravenous r-tPA do not have intracranial vascular imaging as part of their initial evaluation, they should begin receiving intravenous r-tPA before being transported for additional imaging and before being transferred for endovascular treatment. This approach will help minimize onset-to-treatment times, a key driver of efficacy for r-tPA.\(^1\)-\(^6\)

NEW RANDOMIZED CLINICAL TRIALS OF ENDOVASCULAR STROKE TREATMENT

Studies With Primarily Intra-Arterial Fibrinolysis and/or First-Generation Mechanical Embolectomy Devices (Tables 2-4)

SYNTHESIS Expansion was a prospective, randomized, open-label, blinded-end point (PROBE) 2-arm superiority trial that enrolled 362 patients with ischemic stroke eligible for intravenous r-tPA within 4.5 hours of onset and for whom endovascular treatment was possible within 6 hours. No imaging other than nonenhanced computed tomography (CT) was required. The patients were randomized 1:1 to standard dose intravenous r-tPA 0.9 mg/kg or endovascular therapy (intra-
arterial r-tPA, mechanical clot disruption or retrieval, or combination of these approaches). Only 8% had posterior circulation strokes. Median onset to treatment time interval was 2.75 hours in the intravenous r-tPA group and 3.75 hours in the endovascular group. Among the patients who received endovascular treatment, 66% underwent infusion of intra-arterial r-tPA and thrombus fragmentation with a guidewire only; in 34% a device was also deployed. Stent retrievers were used in 14%. Data on rates and efficacy of recanalization were not published. There was no difference in the primary end point of the percentage with good outcome defined as modified Rankin scale (mRS) score of 0 or 1 or in death at 3 months or in symptomatic intracerebral hemorrhage (sICH) at 7 days. There were no significant differences in outcome in subgroups including time to treatment (0-3 or 3-4.5 hours), baseline National Institutes of Health Stroke Scale (NIHSS) score (<11, ≥11), and age (≤67 years, >67 years).

The Interventional Management of Stroke Trial III (IMS III) was a PROBE, 2-arm, superiority trial that enrolled patients with a major ischemic stroke defined by NIHSS score ≥10 who received intravenous r-tPA within 3 hours and were likely to or known to have occlusion of a major cerebral artery. Those who showed clear hypodensity in greater than one third of the middle cerebral artery (MCA) territory on nonenhanced CT were excluded. No other imaging was required. An amendment midway through the trial allowed screening with computed tomographic angiography (CTA) for patients with NIHSS score of ≥8. Over 95% received a clinical diagnosis of anterior circulation stroke. Patients were randomly allocated 1:2 to standard dose intravenous r-tPA (0.9 mg/kg) or to intravenous r-tPA 0.6 mg/kg followed by endovascular therapy with a device and/or intra-arterial r-tPA, if occlusion persisted and if the endovascular intervention could be begun within 5 hours and completed within 7 hours of onset. In the endovascular group, groin puncture occurred at a mean of 208±47 (SD) minutes after stroke onset. Endovascular therapy was
administered in 77% randomized to this treatment group. Intra-arterial r-tPA alone was used in 41% and a device with or without intra-arterial r-tPA in 59%, in only 1.5% were stent retrievers used. Recanalization occurred 325±52 (SD) minutes after stroke onset achieving Thrombolysis In Cerebral Infarction (TICI) grade of 2b/3 in 41%. The trial was stopped early for futility after 656 of projected 900 subjects were enrolled. There was no significant difference in outcome between the intravenous r-tPA only group and the endovascular group for the primary end point of the percentage of patients with a good outcome as measured by mRS score of 0 to 2 or for death at 90 days. In the endovascular group, there was no difference in outcome between those treated <90 minutes versus >90 minutes from intravenous r-tPA to groin puncture. The proportion of patients with mRS score of 0 to 2 at 90 days increased with increasing recanalization.

MR and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) was a PROBE, 2-arm, superiority trial that enrolled 118 patients with large artery occlusion and anterior circulation ischemic stroke within 8 hours who were ineligible for intravenous r-tPA or had persistent vessel occlusion after intravenous r-tPA. Patients were divided into 2 subgroups by pretreatment CT or MRI into those with a favorable or an unfavorable penumbral pattern using imaging criteria based on a previous study. Patients were randomly allocated 1:1 to standard medical care or endovascular therapy (MERCI or Penumbra device with optional intra-arterial r-tPA). Onset to groin puncture in endovascular group was 6.35±1.2 (SD) hours. TICI 2b/3 recanalization was achieved in 25% of the endovascular group. Among all patients, mean scores on the mRS at 90 days did not differ between endovascular and standard medical care, nor was endovascular therapy superior to standard medical care in patients with a favorable penumbral pattern (mean score, 3.9 vs 3.4; \( P=0.23 \)) or in patients with an unfavorable penumbral pattern, (mean score, 4.0 vs 4.4; \( P=0.32 \)).
Studies With Primarily Stent Retrievers (Tables 2-4)

The Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke (MR CLEAN) was a PROBE, 2-arm, superiority trial that studied 500 patients with acute ischemic stroke caused by an proximal intracranial occlusion in the anterior circulation (distal intracranial carotid artery, MCA [M1 or M2], or anterior cerebral artery [A1 or A2]) established with CTA, magnetic resonance angiography (MRA), or digital-subtraction angiography (DSA), and a score of ≥2 on the NIHSS. The steering committee recommended that neuroimaging studies to assess vessel patency should preferably be done before or simultaneously with treatment with intravenous r-tPA. Initiation of endovascular treatment within 6 hours of stroke onset had to be possible. There were different specific exclusion criteria for patients with coagulation abnormalities, previous ischemic stroke, ICH, or severe head trauma depending on whether intra-arterial fibrinolysis was contemplated. Patients who were eligible in agreement with national guidelines received intravenous r-tPA. Those with a nonfavorable response were eligible for inclusion. There was no specified time for observation to determine the response to intravenous r-tPA nor was there an exact definition of what constituted a nonfavorable response, although recovery to level that would not result in administration of intravenous r-tPA was suggested. Patients were randomly allocated 1:1 to either usual care alone or intra-arterial treatment plus usual care. Intra-arterial treatment consisted of arterial catheterization with a microcatheter to the level of occlusion and delivery of a fibrinolytic agent, mechanical thrombectomy, or both. The method of intra-arterial treatment was left to the discretion of the local interventionist. Sixty-four percent of participants had M1 occlusion alone and an additional 27% had occlusion of M1 and the internal carotid artery (ICA). Of the 195 patients in the endovascular group of 233 who received endovascular treatment, onset
to groin puncture was 260 minutes (interquartile range [IQR], 210–313), a stent retriever was used in 81.5% and TICI 2b/3 recanalization was achieved in 59%. The treatment effect was estimated as an odds ratio (OR), adjusted for prespecified prognostic factors that intra-arterial treatment would lead to lower mRS score at 90 days, compared with usual care alone (shift analysis). The adjusted OR was 1.67 (95% confidence interval [CI], 1.21–2.30) in favor of intervention. There was an absolute difference of 13.5% (95% CI, 5.9–21.2) in the rate of functional independence (mRS score, 0–2) in favor of the intervention (32.6% vs 19.1%). There were no significant differences in mortality or the occurrence of sICH. Most patients received intravenous r-tPA (445/500) and showed benefit in subgroup analysis. There were too few patients who did not receive intravenous r-tPA to draw any conclusions. In a subsequent presentation at the 2015 International Stroke Conference, the MR CLEAN investigators reported a stroke onset to reperfusion time of 332 minutes (IQR, 279–394) and demonstrated a marked decline in clinical benefit with time such that the benefit was no longer statistically significant if reperfusion occurred after 6 hours and 19 minutes.

The Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion with Emphasis on Minimizing CT to Recanalization Times (ESCAPE) was a PROBE, 2-arm superiority trial of 316 patients with disabling acute ischemic stroke (NIHSS score >5) who could be randomized up 12 hours after the onset. Groin puncture had to be possible within 60 minutes of CT/CTA. Nonenhanced CT and CTA (preferably multiphase) were performed rapidly with a target door-to-imaging time of 25 minutes to identify participants with a small infarct core (by Alberta Stroke Program Early CT Score [ASPECTS] 6-10 or CT perfusion), an occluded proximal intracranial artery in the anterior circulation (internal carotid, M1 MCA, or ≥2 M2s), and moderate-to-good collateral circulation defined as “the filling of 50% or more of the middle-
cerebral artery pial arterial circulation on CTA (preferably on multiphase CTA).” There were no exclusions for coagulopathy, prior stroke or head trauma. Fifty-eight patients received intravenous r-tPA at a community hospital and then were transferred to an ESCAPE endovascular center. Participants were randomly assigned 1:1 to receive guideline-based care alone or guideline-based care plus endovascular treatment with the use of available thrombectomy devices. The use of retrievable stents and suction through a balloon guide catheter during thrombus retrieval was also recommended. Participants in both groups received intravenous r-tPA within 4.5 hours after onset if they met accepted local guidelines. The primary outcome was the OR that the intervention would lead to lower scores on the mRS at 90 days (shift analysis). After the release of the MR CLEAN results, an interim analysis was conducted earlier than planned that showed that a stopping criterion based on the prespecified O’Brien-Fleming stopping boundary had been crossed and the trial was stopped. For the primary end point, the adjusted OR (indicating the odds of improvement of 1 point on the mRS) was 3.1 (95% CI, 2.0–4.7) favoring endovascular intervention. The proportion of patients with an mRS score of 0 to 2 at 90 days was 53.0% in the intervention group and 29.3% in the control group (P<0.001). Mortality at 90 days was 10.4% in the intervention group and 19.0% in the control group (adjusted rate ratio, 0.5; 95% CI, 0.3–0.8). The rate of sICH clinically determined at the study sites was 3.6% in the endovascular intervention group and 2.7% in the control group (adjusted rate ratio, 1.2; 95% CI, 0.3–4.6). Retrievable stents were used in 130 of the 151 participants (86.1%) who underwent an endovascular procedure. TICI 2b/3 recanalization was observed in 72.4% in the endovascular group. In subgroup analysis, similar benefit was observed in the 235 patients who received intravenous r-tPA (OR, 2.5 [1.6–4.0]) and the 76 who did not (OR, 2.6 [1.1–5.9]). Only 49 participants (15.5%) underwent randomization ≥6 hours after symptom onset; too few to assess efficacy in the 6- to 12-hour time window.18
Solitaire FR with the Intention for Thrombectomy as Primary Endovascular Treatment of Acute Ischemic Stroke (SWIFT PRIME) was a PROBE design trial randomizing 196 patients with acute ischemic stroke and NIHSS scores 8 to 29 who received intravenous r-tPA within 4.5 hours of onset and had CTA or MRA confirmation of intracranial ICA, M1 or carotid terminus occlusion. If CTA or MRA was part of local standard of care, it was performed at initial evaluation prior to commencing intravenous r-tPA; if not, it was performed after review of the initial imaging and signing of informed consent. Groin puncture had to be possible within 6 hours of stroke onset. There were exclusion criteria for coagulopathies. Initially, CT perfusion or multimodal MRI was required and enrollment was restricted to patients with the target mismatch profile (as assessed by specialized software\textsuperscript{19}) and defined as: the ischemic core lesion measured \(\leq 50 \text{ mL} \), the volume of tissue with a time to maximum delay of \(>10 \text{ seconds} \) was \(\leq 100 \text{ mL} \), and the mismatch volume was at least 15 mL and the mismatch ratio was \(>1.8 \). Midway through the trial, the inclusion criteria were modified to accommodate sites with limited perfusion imaging capability. Sites with perfusion imaging were encouraged to continue to use the target mismatch criteria. Sites without perfusion imaging used ASPECTS (ASPECTS >6 was required). A total of 71 patients were enrolled under the initial imaging entry criteria and 125 patients under the revised imaging entry criteria. Perfusion imaging was performed and used for selection in 82.6%. Seventy-three percent of participants had M1 occlusion and 17% had internal carotid artery occlusion. Intravenous r-tPA was administered at an outside hospital in 35%. Participants were randomized 1:1 to treatment with intravenous r-tPA alone or treatment with intravenous r-tPA followed by neurovascular thrombectomy with the use of a stent retriever. After the results of the MR CLEAN trial and the passing of stopping boundaries in the ESCAPE trial were announced, a decision was made to conduct the first interim efficacy analysis a little earlier than originally planned. The results of this
interim efficacy analysis demonstrated that the prespecified criteria for stopping the trial at the first interim analysis were met. The 2 simultaneous success criteria used for the primary end point were both in favor of endovascular intervention: improved distribution (shift analysis) of mRS score at 90 days ($P<0.001$) and increased proportion with mRS score of 0 to 2 at 90 days (60% in the endovascular group and 35% in the nonendovascular group; risk ratio 1.70; 95% CI, 1.23–2.33). There were no significant differences in death or sICH. TICI 2b/3 recanalization was observed in 88% of the endovascular group.\(^20\)

The Extending the Time for Thrombolysis in Emergency Neurological Deficits-Intra-Arterial (EXTEND-IA) was similar in design to SWIFT PRIME. Seventy participants who were eligible using “standard criteria” to receive intravenous r-tPA within 4.5 hours of stroke onset were randomized in a PROBE design either to receive either intravenous r-tPA only or intravenous r-tPA plus endovascular therapy with a stent retriever. Groin puncture had to be within 6 hours and endovascular treatment had to be completed within 8 hours after stroke onset. CT or MRI had to be performed before commencing intravenous r-tPA. Occlusion of the ICA or of M1 or M2 on CTA was required. In addition, CT or MRI perfusion imaging had to show (1) mismatch ratio of $>1.2$, (2) absolute mismatch volume of $>10$ mL, and (3) infarct core lesion volume of $<70$ mL based on specialized software.\(^19\) There were specified exclusion criteria for coagulopathies. Occlusion of the ICA was present in 31% and of M1 in 54%. The coprimary outcomes were reperfusion at 24 hours and early neurologic improvement ($\geq$8-point reduction on the NIHSS or a score of 0 or 1 at day 3). The mRS score at 90 days was a secondary outcome. After the release of the MR CLEAN results, an unplanned interim efficacy analysis was implemented based on a Haybittle-Peto stopping rule. The results of the interim analysis showed that the stopping criteria for efficacy were met and the trial was halted. The percentage of ischemic territory that had
undergone reperfusion at 24 hours was greater in the endovascular therapy group than in the intravenous r-tPA–only group (median, 100% vs 37%; \( P<0.001 \)). Endovascular therapy, initiated at a median of 210 minutes (IQR, 166–251) after the onset of stroke, increased early neurologic improvement at 3 days (80% vs 37%; \( P=0.002 \)) More patients achieved functional independence in the endovascular group (score of 0 to 2 on the mRS, 71% vs 40%; \( P=0.01 \)). There were no significant differences in rates of death or sICH. Recanalization to TICI 2b/3 was achieved in 86% of patients in the endovascular group at a median of 248 minutes (IQR, 204–277) after stroke onset.\(^{21}\)

**Randomized Trial of Revascularization With Solitaire FR Device Versus Best Medical Therapy**

REVASCAT (Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours) was a PROBE design trial randomizing 206 patients with acute ischemic stroke and NIHSS score of \( \geq 6 \) who had intracranial ICA or M1 occlusion by CTA, MRA, or DSA. Patients who had received intravenous r-tPA were eligible, if there was no significant neurological improvement (criteria specified in the protocol) at 30 minutes postinitiation of the infusion and vascular imaging at this time confirmed an eligible occlusion. Groin puncture had to be possible within 8 hours of stroke onset. There were exclusion criteria for coagulopathies. The main exclusion criteria on imaging were ASPECTS of <7 on nonenhanced CT or <6 on DWI-MRI. After the enrollment of 160 patients, the inclusion criteria were modified to include patients up to the age of 85 years (initially 80 years was maximum allowed) with an ASPECTS of >8. Twenty-six percent had ICA occlusion and 65% had M1 occlusion. Participants were randomized 1:1 to receive either medical therapy alone or
thrombectomy with a stent retriever. Intravenous r-tPA was administered to 73%. When results of other similar trials became known, the Data Safety Monitoring Board recommended to stop recruitment because the emerging results showed that equipoise was lost, although the interim results did not reach the prespecified stopping boundaries. The masked steering committee agreed. Because just 1 analysis was performed, adjustment for multiple comparisons was no longer performed, and 95% CIs were reported. The primary outcome analysis showed a common OR of improvement in the distribution of the mRS score (shift analysis) favoring endovascular treatment (adjusted OR, 1.7; 95% CI, 1.05–2.8). The proportion of patients with a mRS score of 0 to 2 at 90 days was 43.7% in the intervention group and 28.2% in the control group (adjusted OR, 2.1; 95% CI, 1.1–4.0). There were no significant differences in death or sICH. Ninety-five percent of those in the endovascular group underwent thrombectomy. TICI 2b/3 recanalization was observed in 66% of the endovascular group. Across the prespecified subgroups, there were no significant interactions according to NIHSS score, vessel-occlusion site, baseline ASPECTS, administration of intravenous r-tPA, age or time of randomization, although for the latter dichotomized at 4.5 hours the P value for interaction was 0.9 with the latter group doing worse. No data are given for those who underwent groin puncture after 6 hours.22

ANALYSIS AND CONCLUSIONS

None of the 3 earlier studies carried out with primarily intra-arterial fibrinolysis and/or first-generation mechanical embolectomy devices showed a benefit of endovascular treatment over intravenous r-tPA in intravenous r-tPA–eligible patients either as a substitute for initial treatment (SYNTHESIS Expansion [Intra-arterial Versus Systemic Thrombolysis for Acute Ischemic Stroke]) or as subsequent intervention in those with persistent large artery occlusion after
intravenous r-tPA (IMS III and MR RESCUE). MR RESCUE also showed no benefit for other patients treated within 8 hours even if selected by multimodal neuroimaging criteria. These studies, using almost exclusively intra-arterial r-tPA and first-generation endovascular devices alone or in combination, achieved recanalization rates of 25% to 41%. The subsequent trials using almost exclusively stent retrievers demonstrated improved results for both recanalization rates and outcome. Studies have shown that clinical outcome improved with increasing effectiveness of recanalization. Those with partial recanalization (TICI 2a) did not do as well as those with near complete/complete recanalization. TICI 2b/3 reflected as differences in discharge disposition (41.0% of TICI 2b/3 group discharged home vs 17.4% of TICI 2a) and functional outcome (34% with a TICI grade of 2a had an mRS score of 0 to 2 at 90 days vs in 49% a TICI grade of 2b/3).\textsuperscript{12,23} TICI 2b/3 recanalization was achieved in 59% to 88% of endovascularly treated subjects in the 5 stent retriever trials, whereas in the previous 3 studies the rate had been 25% to 41%, as mentioned above. All 5 stent retriever studies showed clinical benefit in the endovascular group.

Of the 5 stent retriever trials, MR CLEAN, ESCAPE, and SWIFT PRIME permitted use of salvage intra-arterial fibrinolytic drugs whereas EXTEND-IA and REVASCAT did not. These data do not establish the benefit of intra-arterial fibrinolytic salvage nor can they establish lack of benefit. Such salvage techniques may be reasonable to employ in some clinical circumstances.

The MR RESCUE trial enrolled patients up to 8 hours from symptom onset and showed no benefit from endovascular therapy with first-generation devices regardless of penumbral imaging pattern. Three of the 5 stent retriever studies specified a 6-hour window after stroke onset (2 specified 6 hours to groin puncture; the third specified 6 hours to start treatment). Aggregate data from REVASCAT and ESCAPE with treatment permitted out to 8 and 12 hours show a benefit, but ESCAPE enrolled too few patients after 6 hours to provide useful data and
REVASCAT provides no data about patients who underwent groin puncture between 6 and 8 hours. How much the overall positivity in these 2 trials was completely driven by those treated at shorter times is unknown at this time. The only time dependent data are from the MR CLEAN presentation, which are not consistent with a benefit of treatment beginning after 6 hours. It will take patient level meta-analyses to sort this out.

Every, or nearly every, patient in the 5 stent retriever studies first received intravenous r-tPA. Only REVASCAT stipulated specific the guidelines to be used to determine intravenous r-tPA eligibility (“guidelines provided by the European Stroke Organization [ESO]”). EXTEND-IA refers to “standard criteria” and the 3 other trials used “national guidelines”. Because it is not the purpose of this update is to address eligibility criteria for intravenous r-tPA, we have used the phrase “guidelines from professional medical societies” to address this issue in our recommendations. Too few data are available from the small number of those who did not receive intravenous r-tPA, either for time-based or nontime-based exclusion criteria, to determine with certainty if there are characteristics that identify those who benefited from endovascular treatment.

Two trials (MR CLEAN and REVASCAT) stipulated waiting for a period of time after beginning administration of intravenous r-tPA before proceeding to endovascular therapy, whereas 3 (ESCAPE, SWIFT PRIME, and EXTEND-IA) did not. Based on these data, a waiting period is not necessary to achieve beneficial outcome in these patients.

All of these studies enrolled participants ≥18 years of age. There are no randomized trials of endovascular therapy in patients <18 years of age. Ischemic stroke due to large vessel occlusion is rare in children and young adults relative to older individuals, posing challenges to rigorous study of this clinical scenario. Case reports and case series have documented that high rates of recanalization and favorable outcomes in young patients can be achieved with endovascular
therapy. Ideally, appropriate trials would be done to test the efficacy of endovascular therapy in young patients. Studies in the United States, United Kingdom, Australia, and Canada have shown median times from onset of symptoms to initial brain imaging for pediatric stroke of 8.8 to 16 hours. This problem of diagnostic delay will need to be addressed if acute trials are to be conducted successfully in this population.

Four stent retriever trials used NIHSS scores as eligibility criteria (>2, >5, 8–29, and >5) and the fifth enrolled patients with a similar distribution of NIHSS scores. Based on these trials, there are insufficient data in patients with NIHSS scores <6 to determine if there is an overall net benefit from endovascular therapy in this population. Further randomized trials in patients with low NIHSS scores may be warranted. A NIHSS score of ≥6 was the minimum score used in 2 trials thus fulfilling the AHA’s Level of Evidence grading algorithm for Level A evidence.

Four of the 5 stent retriever trials used a prestroke function eligibility criterion. REVASCAT and SWIFT PRIME used a prestroke mRS score of 0 to 1, EXTEND-IA used mRS scores of 0 to 2, and ESCAPE used Barthel scores of ≥90 to 100. MR CLEAN did not set a threshold and did not provide data on prestroke function. Thus, there are good data from 4 trials for patients with good baseline function (including 2 that required mRS score of 0 to 1) and very little data for those without.

All 5 stent retriever studies required baseline nonenhanced CT or MRI. MR CLEAN did not use a specific ASPECTS criterion for eligibility; it was the only positive trial that permitted enrollment in patients with ASPECTS <6. Although the treatment effect in that trial favored intervention in all 3 ASPECTS subgroups of 0 to 4 (28 patients), 5 to 7 (92 patients), and 8 to 10 (376 patients), the point estimate in the subgroup with an ASPECTS of 0 to 4 was close to unity with wide CIs (adjusted common OR, 1.09; 95% CI, 0.14–8.46). In the ESCAPE trial secondary
analyses based on ASPECTS, the risk ratio favoring intervention was 1.78 (95% CI, 1.31–2.42) for patients with an ASPECTS of 8 to 10, and 2.07 (95% CI, 0.8–5.07) for those with a score of 6 to 8. EXTEND-IA did not report secondary analyses based on ASPECTS. SWIFT PRIME reported similar benefit for those with ASPECTS 8 to 10 (OR, 2.78; 95% CI, 1.4–5.5) and 6 to 7 (OR, 2.68; 95% CI, 0.6–10.53), although the small number of 43 patients in the latter group produced wide confidence bounds. REVASCAT reported greater benefit those with ASPECTS ≥8 (OR, 2.2; 95% CI, 1.1–4.4) than for those with ASPECTS <8 (OR, 1.4; 95% CI, 0.7–2.7) Based on these data, the benefit from endovascular therapy in patients with ASPECTS <6 is uncertain and further randomized, controlled trials are warranted. An ASPECTS of ≥6 was the minimum score used in 2 trials thus fulfilling the AHA’s Level of Evidence grading algorithm for Level A evidence.

Each of the 5 stent retriever trials used different strategies of imaging-based selection criterion in addition to nonenhanced CT or MRI. Common to all was required demonstration, usually with a noninvasive vessel imaging study (CTA or MRA), of a large vessel occlusion prior to randomization. MR CLEAN and REVASCAT also allowed DSA screening to identify a target occlusion. Two trials required noninvasive imaging to be performed at initial evaluation prior to commencing intravenous r-tPA (combined occurrence of no clot at endovascular intervention in 12/200 [6.0%]), a third recommended the same (no clot at endovascular intervention in 8/233 [3.4%]), a fourth stipulated that it be done at all centers for which this was part of local standard of care but otherwise after consent was obtained (no clot at endovascular intervention in 7/98 [7.1%]). REVASCAT stipulated that the imaging study must be completed no more than 90 minutes but ideally within 60 minutes prior to groin puncture and, for patients who had received intravenous tPA, an imaging study assessing vessel patency must be obtained at a minimum of 30
minutes after intravenous r-tPA infusion start (no clot at endovascular intervention in 5/103 [4.9%]). The REVASCAT strategy did not result in a decrease in the number who failed to have a clot present at the time of endovascular intervention compared with the other studies. The goal of intravenous r-tPA and of endovascular therapy is to recanalize the occluded vessel as soon as possible. After initiating intravenous r-tPA, some patients will experience successful recanalization, obviating the need to pursue follow-on endovascular therapy.28 However, because recanalization occurs in only a minority of patients with large vessel occlusion receiving intravenous r-tPA alone (eg, 37.3% in the ESCAPE trial), noninvasive intracranial vascular imaging should proceed without delay before or immediately after initiation of r-tPA to identify the majority of patients who will benefit from follow-on endovascular therapy and expedite its performance. This approach was explicitly taken by investigators in the ESCAPE trial, helping them achieve a median CT to groin puncture time of only 51 minutes.

The ESCAPE, EXTEND-IA, and SWIFT PRIME trials were all initially designed with the intent to select and enroll only patients with small regions of ischemic cores as well as the presence of salvageable brain tissue (SWIFT PRIME and EXTEND-IA) and/or adequate collateral flow (ESCAPE). In ESCAPE, nonenhanced CT and CTA (preferably multiphase) were used to select patients with a target occlusion, small infarct core (ASPECTS 6-10), and moderate to good collateral circulation (filling of ≥50% pial arterial circulation visualized on CTA). EXTEND-IA required demonstration of potentially salvageable brain tissue on perfusion CT (mismatch ratio of >1.2, absolute mismatch volume of >10 mL), as well as ischemic core <70 mL (relative cerebral blood flow <30% of normal). All images were processed on site with a specialized software package.29 Penumbral tissue was defined as regions with Tmax perfusion values >6 seconds that were not included in the ischemic core. SWIFT PRIME excluded patients with evidence of frank
ischemia in greater than one third of the MCA territory or involving >100 mL of tissue. For the first 71 patients enrolled, an additional inclusion criterion was presence of target mismatch defined as: infarct core ≤50 mL (as assessed by specialized software\textsuperscript{19}) and ischemic penumbra ≥15 mL with a mismatch ratio >1.8. After enrollment of the first 71 patients, the investigators switched to the criterion to ASPECTS of ≥6 for sites that did not have CT perfusion capability. To date, subgroup analysis using the various imaging criteria have not been published. In these trials, use of advanced imaging selection criteria had the potential advantage of increasing the likelihood of showing treatment benefit by enhancing the study population with patients most likely to respond to therapy. However, the inherent disadvantage of this study design is the possibility that patients who may have responded to therapy were excluded. In contrast, the MR RESCUE trial was designed specifically to validate imaging biomarkers as a selection tool for endovascular therapy. However, the trial was unable to demonstrate an overall benefit from endovascular therapy with first-generation devices nor in the subgroup with a favorable penumbral pattern. None of the 5 stent retriever studies was designed to validate the utility of the advanced imaging selection criteria themselves in either the early or late time windows. As such, the role of these techniques for patient selection requires further study.

The overwhelming majority of patients in the stent retriever trials had internal carotid artery or proximal MCA (M1) occlusion. The number of patients with isolated M2 lesions was small: ESCAPE, REVASCAT, and SWIFT PRIME excluded patients with isolated M2 occlusions, although small numbers of these patients were enrolled in these trials. The distinction of M1 from M2 can be difficult in some patients owing to early branches of the M1 such as the anterior temporal branch. Inadequate numbers of patients with occlusion of other vessels, including M3,
anterior cerebral arteries and those in the vertebrobasilar circulation, were enrolled to allow assessment of clinical efficacy in these territories as well.

The usefulness of mechanical thrombectomy devices other than stent retrievers is not well established, either for technical efficacy or clinical benefit. Most of the patients in MR CLEAN and ESCAPE, and all of the patients in EXTEND-IA, SWIFT-PRIME, and REVASCAT who underwent an endovascular procedure were treated with a stent retriever (81.5% in MR CLEAN, 86.1% in ESCAPE). These trials were not designed to demonstrate the superiority of stent retrievers over other devices, such as snares or suction aspiration systems. Therefore, the recommendation that stent retrievers are preferred over MERCI (Mechanical Embolus Removal in Cerebral Ischemia) is unchanged from the previous guidelines based on the SWIFT and TREVO 2 [Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke] studies. At the time these guidelines are written, there are no published randomized clinical trials demonstrating clinical benefit nor comparing its relative effectiveness of other devices versus stent retrievers.

None of these studies specified requirements for use of a proximal balloon guide catheter, large bore distal access catheter or cervical guide catheter alone in conjunction with stent retrievers. The concomitant use of distal access suction catheters during stent retriever mechanical thrombectomy has been described in retrospective case series. The advantages of the combined stent-aspiration technique include: a flexible large bore catheter in a tri-axial technique which provides stability for the stent-retriever, flow reversal to prevent distal embolization during stent-retrieval of the thrombus, and the potential synergistic effect of both techniques of suction aspiration and stent retrieval used simultaneously. Clinical experience has shown the
combination of balloon guide catheters or distal access/aspiration catheters with stent retrievers to provide rapid, effective and safe recanalization.\textsuperscript{35,36}

All the stent retriever trials allowed inclusion of patients with proximal cervical carotid stenosis and all but one allowed inclusion of patients with complete atherosclerotic cervical carotid occlusion (SWIFT PRIME). One difficulty with this exclusion is that differentiating complete cervical carotid occlusion from a distal ICA occlusion is often not possible on CTA or MRA.\textsuperscript{37} The number of patients with cervical carotid occlusion or stenosis was not consistently reported but substantial, ranging from 18.6\% (REVASCAT) to 32.2\% (MR CLEAN). Stenting of the underlying stenosis or occlusion was discouraged in the ESCAPE protocol. Thirty of the 75 patients with carotid stenosis or occlusion in the intervention arm were stenting during the thrombectomy procedure in MR CLEAN. Nine of the 19 patients with carotid occlusion in REVASCATS were stented at the time of thrombectomy. The management of the underlying lesion was not reported in the other trials. Outcomes for the subgroup of patients with carotid occlusion were reported in ESCAPE (adjusted OR, 9.6; 95\% CI, 2.6–35.5) and MR CLEAN (adjusted OR, 1.43; 95\% CI, 0.78–2.64). Although thrombectomy for patients with cervical ICA occlusion is clearly indicated by these data, the optimal management of the underlying stenosis is not clear. There are several potential advantages and disadvantages for angioplasty and stenting at the time of thrombectomy. Although immediate revascularization may reduce the risk of recurrent stroke, urgent stenting generally requires antiplatelet prophylaxis which has been associated with intracranial hemorrhage in this setting. Carotid stenting and intracranial thrombectomy for treatment of acute stroke due to tandem occlusions with aggressive antiplatelet therapy may be associated with a high incidence of intracranial hemorrhage.\textsuperscript{38,39} In addition, there is some risk for thromboembolic stroke at the time of stenting. Further studies are indicated.
General anesthesia with intubation and conscious sedation are the 2 most frequently used anesthetic approaches for patients with an acute ischemic stroke receiving endovascular therapy.40 There are no dedicated randomized controlled clinical trials addressing this issue. The MR CLEAN investigators have reported that the outcomes of the 79 patients in the endovascular group who received general anesthesia were not different from the 267 nonendovascular control patients (adjusted OR, 1.09; 95% CI, 1.69–1.71.), whereas for the 137 endovascular patients who did not receive general anesthesia the outcomes were better than for the 267 control patients (adjusted OR, 2.13; 95% CI, 1.46–3.11).41 Similar data showing worse outcomes in those undergoing general anesthesia as compared to conscious sedation for endovascular were reported in a recent meta-analysis of 9 nonrandomized studies comprising 1956 patients (814 received general anesthesia and 1142 received conscious sedation) with the largest study having 1079 patients and the smallest study having 66 patients.42 In this meta-analysis, compared with conscious sedation, general anesthesia was linked to lower odds of a favorable functional outcome (OR, 0.43; 95% CI, 0.35–0.80; P<0.01), higher odds of mortality (OR, 2.59; 95% CI, 1.87–3.58; P<0.01), and fewer adverse respiratory events (OR, 2.09; 95% CI, 1.36–3.23; P<0.01). No significant differences in the rates of asymptomatic ICH, sICH, or other vascular complications were seen between the groups. Furthermore, mean time to groin puncture, mean procedure time, and mean time from symptom onset to revascularization were not significantly different between the 2 techniques. There was substantial heterogeneity (I²>50%) across the included studies for the outcomes of functional status (I²=55%), time to revascularization (I²=60%), time to groin puncture (I²=83%), and procedure time (I²=91%). In most of the included studies, patients who received general anesthesia were typically in worse clinical condition at baseline as reflected by their comparatively higher NIHSS scores. Only 6 of the 9 studies included information on baseline NIHSS score. Adjusting
for NIHSS score by using metaregression for the odds of having good functional outcomes yielded an OR of 0.38; which was similar to the unadjusted estimate of 0.43; however, the 95% CI became statistically insignificant (0.12–1.22). As such, even after adjusting for initial stroke severity, the possibility of selection bias cannot be completely excluded. Patients with more severe strokes or poorer baseline conditioning may have received general anesthesia or may have been intubated before the procedure due to an actual or expected inability to maintain airway patency. Moreover, it is also possible that lower recanalization rates observed with general anesthesia in some studies were due to greater numbers of more technically difficult vascular occlusions in those who received general anesthesia. On balance, data from published data broadly indicate that conscious sedation might be safer and more effective than general anesthesia in the setting of endovascular therapy for acute ischemic stroke. However, specific randomized controlled trial data are warranted to definitively establish conscious sedation as the preferred anesthetic technique in patients receiving endovascular treatment for acute ischemic stroke. Clinical trials are ongoing (NCT01872884, NCT02317237).

The AHA’s Level of Evidence grading algorithm requires high-quality evidence from >1 randomized controlled trial for Level of Evidence A. In accordance with this algorithm and the results from the 5 recent studies with stent retrievers summarized above, we concluded that the data supported Class I, Level of Evidence A recommendations but only for a carefully defined group of patients (see recommendation 2). Subsequent meta-analysis of patient level data may allow these recommendations to be expanded.
RECOMMENDATIONS

Endovascular Interventions

1. Patients eligible for intravenous r-tPA should receive intravenous r-tPA even if endovascular treatments are being considered (Class I; Level of Evidence A). (Unchanged from the 2013 guideline)

2. Patients should receive endovascular therapy with a stent retriever if they meet all the following criteria (Class I; Level of Evidence A). (New recommendation):
   - (a) prestroke mRS score 0 to 1,
   - (b) acute ischemic stroke receiving intravenous r-tPA within 4.5 hours of onset according to guidelines from professional medical societies,
   - (c) causative occlusion of the internal carotid artery or proximal MCA (M1),
   - (d) age ≥18 years,
   - (e) NIHSS score of ≥6,
   - (f) ASPECTS of ≥6, and
   - (g) treatment can be initiated (groin puncture) within 6 hours of symptom onset

3. As with intravenous r-tPA, reduced time from symptom onset to reperfusion with endovascular therapies is highly associated with better clinical outcomes. To ensure benefit, reperfusion to TICI grade 2b/3 should be achieved as early as possible and within 6 hours of stroke onset (Class I; Level of Evidence B-R). (Revised from the 2013 guideline)

4. When treatment is initiated beyond 6 hours from symptom onset, the effectiveness of endovascular therapy is uncertain for patients with acute ischemic stroke who have causative occlusion of the internal carotid artery or proximal MCA (M1) (Class IIb; Level of Evidence C). Additional randomized trial data are needed. (New recommendation)
5. In carefully selected patients with anterior circulation occlusion who have contraindications to intravenous r-tPA, endovascular therapy with stent retrievers completed within 6 hours of stroke onset is reasonable (Class IIA; Level of Evidence C). There are inadequate data available at this time to determine the clinical efficacy of endovascular therapy with stent retrievers for those patients whose contraindications are time-based or nontime based (eg, prior stroke, serious head trauma, hemorrhagic coagulopathy, or receiving anticoagulant medications). (New recommendation)

6. Although the benefits are uncertain, use of endovascular therapy with stent retrievers may be reasonable for carefully selected patients with acute ischemic stroke in whom treatment can be initiated (groin puncture) within 6 hours of symptom onset and who have causative occlusion of the M2 or M3 portion of the MCAs, anterior cerebral arteries, vertebral arteries, basilar artery, or posterior cerebral arteries (Class IIB; Level of Evidence C). (New recommendation)

7. Endovascular therapy with stent retrievers may be reasonable for some patients <18 years of age with acute ischemic stroke who have demonstrated large vessel occlusion in whom treatment can be initiated (groin puncture) within 6 hours of symptom onset, but the benefits are not established in this age group (Class IIB; Level of Evidence C). (New recommendation)

8. Although the benefits are uncertain, use of endovascular therapy with stent retrievers may be reasonable for patients with acute ischemic stroke in whom treatment can be initiated (groin puncture) within 6 hours of symptom onset and who have prestroke mRS score of >1, ASPECTS <6, or NIHSS score <6 and causative occlusion of the internal carotid artery
or proximal MCA (M1) (Class IIb; Level of Evidence B-R). Additional randomized trial data are needed. (New recommendation)

9. Observing patients after intravenous r-tPA to assess for clinical response before pursuing endovascular therapy is not required to achieve beneficial outcomes and is not recommended. (Class III; Level of Evidence B-R). (New recommendation)

10. Use of stent retrievers is indicated in preference to the MERCI device. (Class I; Level of Evidence A). The use of mechanical thrombectomy devices other than stent retrievers may be reasonable in some circumstances (Class IIb, Level B-NR). (New recommendation)

11. The use of proximal balloon guide catheter or a large bore distal access catheter rather than a cervical guide catheter alone in conjunction with stent retrievers may be beneficial (Class IIA; Level of Evidence C). Future studies should examine which systems provide the highest recanalization rates with the lowest risk for nontarget embolization. (New recommendation)

12. The technical goal of the thrombectomy procedure should be a TICI 2b/3 angiographic result to maximize the probability of a good functional clinical outcome (Class I; Level of Evidence A). Use of salvage technical adjuncts including intra-arterial fibrinolysis may be reasonable to achieve these angiographic results, if completed within 6 hours of symptom onset (Class IIb; Level of Evidence B-R). (New recommendation)

13. Angioplasty and stenting of proximal cervical atherosclerotic stenosis or complete occlusion at the time of thrombectomy may be considered but the usefulness is unknown (Class IIb; Level of Evidence C). Future randomized studies are needed.

14. Initial treatment with intra-arterial fibrinolysis is beneficial for carefully selected patients with major ischemic strokes of <6 hours’ duration caused by occlusions of the MCA (Class
Level of Evidence B-R). However, these data derive from clinical trials that no longer reflect current practice, including use of fibrinolytic drugs that are not available. A clinically beneficial dose of intra-arterial r-tPA is not established, and r-tPA does not have FDA approval for intra-arterial use. As a consequence, endovascular therapy with stent retrievers is recommended over intra-arterial fibrinolysis as first-line therapy (Class I; Level of Evidence E). (Revised from the 2013 guideline)

15. Intra-arterial fibrinolysis initiated within 6 hours of stroke onset in carefully selected patients who have contraindications to the use of intravenous r-tPA might be considered, but the consequences are unknown (Class IIb; Level of Evidence C). (Revised from 2013 guideline)

16. It might be reasonable to favor conscious sedation over general anesthesia during endovascular therapy for acute ischemic stroke. However, the ultimate selection of anesthetic technique during endovascular therapy for acute ischemic stroke should be individualized based on patient risk factors, tolerance of the procedure, and other clinical characteristics. Randomized trial data are needed (Class IIb; Level of Evidence C). (New recommendation)

**Imaging**

1. Emergency imaging of the brain is recommended before initiating any specific treatment for acute stroke (Class I; Level of Evidence A). In most instances, nonenhanced CT will provide the necessary information to make decisions about emergency management. (Unchanged from the 2013 guideline)
2. If endovascular therapy is contemplated, a noninvasive intracranial vascular study is strongly recommended during the initial imaging evaluation of the acute stroke patient but should not delay intravenous r-tPA if indicated. For patients who qualify for intravenous r-tPA according to guidelines from professional medical societies, initiating intravenous r-tPA before noninvasive vascular imaging is recommended for patients who have not had noninvasive vascular imaging as part of their initial imaging assessment for stroke. Noninvasive intracranial vascular imaging should then be obtained as quickly as possible (Class I; Level of Evidence A). (New recommendation)

3. The benefits of additional imaging beyond CT and CTA or MR and MRA, such as CT perfusion or diffusion- and perfusion-weighted imaging, for selecting patients for endovascular therapy are unknown (Class IIb; Level of Evidence C). Further randomized, controlled trials may be helpful to determine whether advanced imaging paradigms employing CT perfusion, CTA, and MRI perfusion and diffusion imaging, including measures of infarct core, collateral flow status, and penumbra, are beneficial for selecting patients for acute reperfusion therapy who are within 6 hours of symptom onset and have an ASPECTS < 6. Further randomized, controlled trials should be done to determine whether advanced imaging paradigms using CT perfusion and MRI perfusion, CTA, and diffusion imaging, including measures of infarct core, collateral flow status, and penumbra, are beneficial for selecting patients for acute reperfusion therapy who are beyond 6 hours from symptom onset. (New recommendation)
Systems of Stroke Care

1. Patients should be transported rapidly to the closest available certified primary stroke center or comprehensive stroke center or, if no such centers exist, the most appropriate institution that provides emergency stroke care as described in the 2013 guidelines (*Class I; Level of Evidence A*). In some instances, this may involve air medical transport and hospital bypass. (Unchanged from the 2013 guideline)

2. Regional systems of stroke care should be developed. These should consist of consisting of:
   
   (a) Healthcare facilities that provide initial emergency care including administration of intravenous r-tPA, including primary stroke centers, comprehensive stroke centers, and other facilities.

   (b) Centers capable of performing endovascular stroke treatment with comprehensive periprocedural care, including comprehensive stroke centers and other healthcare facilities, to which rapid transport can be arranged when appropriate (*Class I; Level of Evidence A*). (Revised from the 2013 guideline)

3. It may be useful for primary stroke centers and other healthcare facilities that provide initial emergency care including administration of intravenous r-tPA to develop the capability of performing emergency noninvasive intracranial vascular imaging to most appropriately select patients for transfer for endovascular intervention and reduce time to endovascular treatment (*Class IIb; Level of Evidence C*). (Revised from the 2013 guideline)

4. Endovascular therapy requires the patient to be at an experienced stroke center with rapid access to cerebral angiography and qualified neurointerventionalists. Systems should be designed, executed and monitored to emphasize expeditious assessment and treatment.
Outcomes on all patients should be tracked. Facilities are encouraged to define criteria that can be used to credential individuals who can perform safe and timely intra-arterial revascularization procedures (Class I; Level of Evidence E). (Revised from the 2013 guideline)

REFERENCES


## Writing Group Disclosures

<table>
<thead>
<tr>
<th>Writing Group Member</th>
<th>Employment</th>
<th>Research Grant</th>
<th>Other Research Support</th>
<th>Speakers’ Bureau/ Honoraria</th>
<th>Expert Witness</th>
<th>Ownership Interest</th>
<th>Consultant/ Advisory Board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>William J. Powers</td>
<td>University of North Carolina</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Colin P. Derdeyn</td>
<td>Washington University</td>
<td>Microvention*; Penumbra*; SILK Road*</td>
<td>None</td>
<td>None</td>
<td>Medico-legal cases (defense)*</td>
<td>Pulse Therapeutics*</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>José Biller</td>
<td>Loyola University</td>
<td>None</td>
<td>DSMB (ongoing clinical trial)*</td>
<td>None</td>
<td>Expert witness (defense)*</td>
<td>None</td>
<td>Frontiers in Neurology (Editor)<em>; Journal of Stroke and Cerebrovascular Disease (Editor)</em>; Stroke Editorial Board Member for Up-To-Date*</td>
<td>None</td>
</tr>
<tr>
<td>Christopher S. Coffey</td>
<td>University of Iowa</td>
<td>NIH/NINDS†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Brian L. Hoh</td>
<td>University of Florida</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Writing Group Member</td>
<td>Employment</td>
<td>Research Grant</td>
<td>Other Research Support</td>
<td>Speakers’ Bureau/Honoraria</td>
<td>Expert Witness</td>
<td>Ownership Interest</td>
<td>Consultant/Advisory Board</td>
<td>Other</td>
</tr>
<tr>
<td>----------------------</td>
<td>---------------------------------</td>
<td>------------------------------------</td>
<td>------------------------</td>
<td>---------------------------</td>
<td>----------------</td>
<td>--------------------</td>
<td>-----------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Edward C. Jauch</td>
<td>Medical University of South Carolina</td>
<td>Covidien*; Genentech*; Penumbra*; Stryker*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Karen C. Johnston</td>
<td>University of Virginia</td>
<td>FDA*; NIH/NINDS†; NIH/NHLBI†; NINDS*; Roche/Genentech*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>S. Claiborne Johnston</td>
<td>University of Texas</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Alexander A. Khalessi</td>
<td>University of California, San Diego</td>
<td>Covidien*; Microvention*; Penumbra*; Sequent*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Lazarus*</td>
<td>Codman*; Medtronic-Covidien-ev3†; Microvention*; Penumbra*; Stryker*</td>
<td>None</td>
</tr>
<tr>
<td>Chelsea S. Kidwell</td>
<td>University of Arizona</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>James F. Meschia</td>
<td>Mayo Clinic</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Bruce Ovbiagele</td>
<td>Medical University of South Carolina</td>
<td>NIH†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition. *Modest. †Significant.

<table>
<thead>
<tr>
<th>Writing Group Member</th>
<th>Employment</th>
<th>Research Grant</th>
<th>Other Research Support</th>
<th>Speakers’ Bureau/ Honoraria</th>
<th>Expert Witness</th>
<th>Ownership Interest</th>
<th>Consultant/ Advisory Board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dileep R. Yavagal</td>
<td>University of Miami Miller School of Medicine</td>
<td>Covidien/ Medtronic*; Penumbra*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Covidien/ Medtronic*; Aldagen/ Cytomedix*</td>
<td>None</td>
</tr>
</tbody>
</table>

DOI: 10.1161/STR.0000000000000074
### Reviewer Disclosures

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Employment</th>
<th>Research Grant</th>
<th>Research Support</th>
<th>Speakers’ Bureau/ Honoraria</th>
<th>Expert Witness</th>
<th>Ownership Interest</th>
<th>Consultant/Advisory Board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sepideh Amin-Hanjani</td>
<td>University of Illinois at Chicago</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Nicholas Bambakidis</td>
<td>University Hospitals Case Medical Center</td>
<td>AHA†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Karen Furie</td>
<td>Rhode Island Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Laura Heitsch</td>
<td>Washington University</td>
<td>AHA†; EMF†</td>
<td>None</td>
<td>VINDICO†; Genentech†</td>
<td>None</td>
<td>None</td>
<td>Genentech*</td>
<td>None</td>
</tr>
<tr>
<td>Philip Meyers</td>
<td>Columbia University</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Peter Panagos</td>
<td>Washington University</td>
<td>None</td>
<td>None</td>
<td>Genentech†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

*Modest.
†Significant.
<table>
<thead>
<tr>
<th>CLASS (STRENGTH) OF RECOMMENDATION</th>
<th>LEVEL (QUALITY) OF EVIDENCE‡</th>
</tr>
</thead>
</table>
| CLASS I (STRONG)  
Benefit >>> Risk  
Suggested phrases for writing recommendations:  
- Is recommended  
- Is indicated/useful/effective/beneficial  
- Should be performed/administered/other  
- Comparative-Effectiveness Phrases†:  
  - Treatment/strategy A is recommended/indicated in preference to treatment B  
  - Treatment A should be chosen over treatment B | LEVEL A  
- High-quality evidence‡ from more than 1 RCTs  
- Meta-analyses of high-quality RCTs  
- One or more RCTs corroborated by high-quality registry studies |
| CLASS IIa (MODERATE)  
Benefit >> Risk  
Suggested phrases for writing recommendations:  
- Is reasonable  
- Can be useful/effective/beneficial  
- Comparative-Effectiveness Phrases†:  
  - Treatment/strategy A is probably recommended/indicated in preference to treatment B  
  - It is reasonable to choose treatment A over treatment B | LEVEL B-R  
- Moderate-quality evidence‡ from 1 or more RCTs  
- Meta-analyses of moderate-quality RCTs |
| CLASS IIb (WEAK)  
Benefit ≥ Risk  
Suggested phrases for writing recommendations:  
- May/might be reasonable  
- May/might be considered  
- Usefulness/effectiveness is unknown/unclear/uncertain or not well established | LEVEL B-NR  
- Moderate-quality evidence‡ from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies  
- Meta-analyses of such studies |
| CLASS III: No Benefit (MODERATE)  
(Generally, LOE A or B use only)  
Benefit = Risk  
Suggested phrases for writing recommendations:  
- Is not recommended  
- Is not indicated/useful/effective/beneficial  
- Should not be performed/administered/other | LEVEL C  
- Randomized or nonrandomized observational or registry studies with limitations of design or execution  
- Meta-analyses of such studies  
- Physiological or mechanistic studies in human subjects |
| CLASS III: Harm (STRONG)  
Risk > Benefit  
Suggested phrases for writing recommendations:  
- Potentially harmful  
- Causes harm  
- Associated with excess morbidity/mortality  
- Should not be performed/administered/other | LEVEL E  
Consensus of expert opinion based on clinical experience when evidence is insufficient, vague, or conflicting |

COR and LOE are determined independently (any COR may be paired with any LOE).

A recommendation with LOE C or E does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

* The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).

† For comparative-effectiveness recommendations (COR I and IIa; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

‡ The method of assessing quality is evolving, including the application of standardized, widely used, and preferably validated evidence grading tools; and for systematic reviews, the incorporation of an Evidence Review Committee.

COR indicates Class of Recommendation; LOE, Level of Evidence; NR, nonrandomized; R, randomized; and RCT, randomized controlled trial.
<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment Groups</th>
<th>Active vs Control</th>
<th>IV rtPA eligible</th>
<th>Age (yrs)</th>
<th>Time</th>
<th>Territory</th>
<th>NIHSS</th>
<th>Pre-stroke Function</th>
<th>Anticoagulation/ Coagulopathy</th>
<th>ASPECTS</th>
<th>Vascular Imaging</th>
<th>Other Imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYNTHESIS Expansion</td>
<td>IA drug/any device/both vs IV rtPA</td>
<td>required</td>
<td>18-80</td>
<td>6 hrs to IAT</td>
<td>any</td>
<td>≤ 25</td>
<td>≤ 25</td>
<td>mRS 0-1</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>IMS III</td>
<td>2/3 standard dose IV rtPA + IA drug/any device/both vs IV rtPA</td>
<td>required, ≤ 3 hrs</td>
<td>18-82</td>
<td>5 hrs to IAT</td>
<td>any</td>
<td>≥ 10 or ≤ 25</td>
<td>mRS O-2</td>
<td>exclusion criteria</td>
<td>&lt; 4</td>
<td>No</td>
<td>&gt; 1/3 MCA excluded</td>
<td>No</td>
</tr>
<tr>
<td>MR RESCUE</td>
<td>Standard (± IV rtPA) + MERCI or Penumbra</td>
<td>not required</td>
<td>18-85</td>
<td>8 hrs to IAT</td>
<td>anterior circulation</td>
<td>6-29</td>
<td>mRS O-2</td>
<td>exclusion criteria</td>
<td>No</td>
<td>CTA, MRA</td>
<td>multimodal CT/MR for stratification</td>
<td></td>
</tr>
<tr>
<td>MR CLEAN</td>
<td>Standard (± IV rtPA) + IA UK, rtPA, device vs Standard (± IV rtPA)</td>
<td>not required</td>
<td>&gt;18</td>
<td>6 hrs to IAT</td>
<td>anterior circulation</td>
<td>&gt;2</td>
<td>none</td>
<td>exclusion criteria</td>
<td>No</td>
<td>CTA, MRA, DSA</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>ESCAPE</td>
<td>Standard (± IV rtPA) + stent retriever vs Standard (± IV rtPA)</td>
<td>not required</td>
<td>&gt; 18</td>
<td>12 hrs to randomisation</td>
<td>ICA/MCA</td>
<td>&gt;5</td>
<td>Barthel ≥ 90</td>
<td>no exclusion criteria</td>
<td>≥6</td>
<td>CTA</td>
<td>multiphase CTA or CT perfusion for detection of core size and collaterals</td>
<td></td>
</tr>
<tr>
<td>SWIFT PRIME</td>
<td>Standard (± IV rtPA) + stent retriever vs Standard (± IV rtPA)</td>
<td>required</td>
<td>18-80</td>
<td>6 hrs to groin</td>
<td>ICA/M1</td>
<td>8-29</td>
<td>mRS0-1</td>
<td>exclusion criteria</td>
<td>≥6</td>
<td>CTA, MRA</td>
<td>CT or MRI mismatch for first 71 ASPECTS ≥6 for remaining 125</td>
<td></td>
</tr>
<tr>
<td>EXTEND-IA</td>
<td>Standard (± IV rtPA) + stent retriever vs Standard (± IV rtPA)</td>
<td>required</td>
<td>≥ 18</td>
<td>6 hrs to groin complete in 8</td>
<td>anterior circulation</td>
<td>none</td>
<td>mRS ≤ 1</td>
<td>exclusion criteria</td>
<td>No</td>
<td>CTA, MRA</td>
<td>CT/MRI Mismatch</td>
<td></td>
</tr>
<tr>
<td>REVASCAT</td>
<td>Standard (± IV rtPA) + stent retriever vs Standard (± IV rtPA)</td>
<td>not required</td>
<td>18-80 (85)</td>
<td>8 hrs to groin</td>
<td>ICA/M1</td>
<td>≥6</td>
<td>mRS0-1</td>
<td>exclusion criteria</td>
<td>≥ 7 (NECT)</td>
<td>≥ 6</td>
<td>MRI-DWI required if ≥ 4.5 hrs</td>
<td></td>
</tr>
</tbody>
</table>

Table 2

Selected Eligibility Criteria for Recent Randomized Clinical Trial Of Endovascular Treatments for Acute Ischemic Stroke

Powers et al 43

DOI: 10.1161/STR.0000000000000074
<table>
<thead>
<tr>
<th>Study</th>
<th>Participants (Active/Control)</th>
<th>Table 3 Selected Patient Characteristics for Recent Randomized Clinical Trial Of Endovascular Treatments for Acute Ischemic Stroke</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYNTHESIS EXPANSION</td>
<td>181/181</td>
<td><strong>Age (yrs) Mean± SD (IQR)</strong> 66±12/67±11 <strong>NIHSS Median, <a href="Range">IQR</a></strong> 13(9-17)/13(9-18) <strong>Territory (%) ASPECTS Median, [IQR]</strong> 88/94 anterior <strong>Device Deployment in Active Group</strong> 92% IA rtPA alone 60% device added 34% 77% <strong>Onset to IV rtPA (min) Mean ± SD, Median (IQR)</strong> 1.79 (2.13-3.35) hrs <strong>Time Onset to Groin (min) Mean ± SD, Median (IQR)</strong> 3.79 (3.13-4.35) hrs  to clot <strong>Recanalization TICI 2b/3</strong> 91% <strong>Time to Reperfusion</strong> 2.75 (2.33,3.33) hrs</td>
</tr>
<tr>
<td>IMS III</td>
<td>434/222</td>
<td>**Age (yrs) 68/68 ** <strong>NIHSS Median, <a href="Range">IQR</a></strong> 17 (7-40)//16(8-30) <strong>Territory (%) 97/97 anterior (clinical)</strong> <strong>Device Deployment in Active Group</strong> 41% IA rtPA alone 38% IA rtPA + device 21% device only 1.5% stent retriever <strong>Onset to IV rtPA (min) Mean ± SD, Median (IQR)</strong> 122±34//111±34 <strong>Time Onset to Groin (min) Mean ± SD, Median (IQR)</strong> 208±47 // 41% <strong>Recanalization TICI 2b/3</strong> 91% <strong>Time to Reperfusion</strong> 3.75 (2.33,4.35) hrs to clot</td>
</tr>
<tr>
<td>MR RESCUE</td>
<td>64/54</td>
<td>**Age (yrs) 66±15 ** <strong>NIHSS Median, <a href="Range">IQR</a></strong> 17 (12-21) <strong>Territory (%)</strong> KCA 20/13 M 61/72 M 61/72 <strong>Device Deployment in Active Group</strong> 95% <strong>Onset to IV rtPA (min) Mean ± SD, Median (IQR)</strong> 6.31±1.2 hrs. <strong>Time Onset to Groin (min) Mean ± SD, Median (IQR)</strong> 25% <strong>Recanalization TICI 2b/3</strong> 95% <strong>Time to Reperfusion</strong> 6.31±1.2 hrs.</td>
</tr>
<tr>
<td>MR CLEAN</td>
<td>233/267</td>
<td>**Age (yrs) 66 (50-78)//66 (50-76) ** <strong>NIHSS Median, <a href="Range">IQR</a></strong> 17 (14-21)//15 (13-22) [4-38] <strong>Territory (%)</strong> 9 (7-10)/9 (8-10) <strong>Device Deployment in Active Group</strong> 81.7% stent retriever 41% IA rtPA 21% <strong>Onset to IV rtPA (min) Mean ± SD, Median (IQR)</strong> 85 (67-105)//87 (85-116) <strong>Time Onset to Groin (min) Mean ± SD, Median (IQR)</strong> 260 (210-313) <strong>Recanalization TICI 2b/3</strong> 58.70% <strong>Time to Reperfusion</strong> 332 (279-394)</td>
</tr>
<tr>
<td>ESCAPE</td>
<td>185/150</td>
<td>**Age (yrs) 71 (60-81)//70 (60-81) ** <strong>NIHSS Median, <a href="Range">IQR</a></strong> 16 (13-20)//17 (12-20) <strong>Territory (%)</strong> 9 (8-10)/9 (8-10) <strong>Device Deployment in Active Group</strong> 72.7% stent retriever 91.30% 71.40% <strong>Onset to IV rtPA (min) Mean ± SD, Median (IQR)</strong> 110 (100-120)//110 (100-120) <strong>Time Onset to Groin (min) Mean ± SD, Median (IQR)</strong> 110 (100-120)//110 (100-120) <strong>Recanalization TICI 2b/3</strong> 72% <strong>Time to Reperfusion</strong> 72%</td>
</tr>
<tr>
<td>SWIFT PRIME</td>
<td>98/98</td>
<td>**Age (yrs) 68±13//68±11 ** <strong>NIHSS Median, <a href="Range">IQR</a></strong> 17 (13-20)/17 (13-20) <strong>Territory (%)</strong> 9 (7-10)/9 (8-10) <strong>Device Deployment in Active Group</strong> 88.80% all stent retriever 88.80% 88.80% <strong>Onset to IV rtPA (min) Mean ± SD, Median (IQR)</strong> 110.5 (95-155)/110.5 (95-155) <strong>Time Onset to Groin (min) Mean ± SD, Median (IQR)</strong> 88% <strong>Recanalization TICI 2b/3</strong> 88% <strong>Time to Reperfusion</strong> 88%</td>
</tr>
<tr>
<td>EXTEND-IA</td>
<td>35/35</td>
<td>**Age (yrs) 69±12//70±12 ** <strong>NIHSS Median, <a href="Range">IQR</a></strong> 17 (13-20)/17 (13-20) <strong>Territory (%)</strong> 77% 77% 77% <strong>Device Deployment in Active Group</strong> all stent retriever 224/165-275 <strong>Onset to IV rtPA (min) Mean ± SD, Median (IQR)</strong> 127 (105-162)/145 (105-180) <strong>Time Onset to Groin (min) Mean ± SD, Median (IQR)</strong> 86% <strong>Recanalization TICI 2b/3</strong> 86% <strong>Time to Reperfusion</strong> 249 (204-277)</td>
</tr>
<tr>
<td>REVASCAT</td>
<td>101/103</td>
<td>**Age (yrs) 66 ± 11/67±10 ** <strong>NIHSS Median, <a href="Range">IQR</a></strong> 17[14-20]/17 (12-19) <strong>Territory (%)</strong> 7[6-9]/8(6-9) <strong>Device Deployment in Active Group</strong> all stent retriever 95% 88% 88% <strong>Onset to IV rtPA (min) Mean ± SD, Median (IQR)</strong> 118 (90-150)/110 (88-138) <strong>Time Onset to Groin (min) Mean ± SD, Median (IQR)</strong> 66% <strong>Recanalization TICI 2b/3</strong> 66% <strong>Time to Reperfusion</strong> 355 (260-410)</td>
</tr>
<tr>
<td>Study</td>
<td>Symptomatic ICH Time Subgroups</td>
<td>ASPECTS Subgroups</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td></td>
<td>Active (%)</td>
<td>Control (%)</td>
</tr>
<tr>
<td></td>
<td>IV rtPA</td>
<td>NIHSS Subgroups</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SYNTHESIS</td>
<td>EXPANSION</td>
</tr>
<tr>
<td></td>
<td>mRS 0-1 at 3 mos</td>
<td>30.4%</td>
</tr>
<tr>
<td></td>
<td>≤ 67</td>
<td>153</td>
</tr>
<tr>
<td></td>
<td>mRS 0-2 at 90 d</td>
<td>40.8%</td>
</tr>
<tr>
<td></td>
<td>MR RESCUE</td>
<td>mean mRS</td>
</tr>
<tr>
<td></td>
<td>MR CLEAN</td>
<td>improvement mRS at 90 d</td>
</tr>
<tr>
<td></td>
<td>ESCAPE</td>
<td>improvement mRS at 90 d</td>
</tr>
<tr>
<td></td>
<td>SWIFT PRIME</td>
<td>Rankin shift , 5&amp;6 combined</td>
</tr>
<tr>
<td></td>
<td>REVASCAT</td>
<td>improvement mRS at 90 d</td>
</tr>
<tr>
<td></td>
<td>EXTEND-IA</td>
<td>Median Reperfusion at 24 hours</td>
</tr>
<tr>
<td></td>
<td>SWIFT PRIME</td>
<td>Rankin shift , 5&amp;6 combined</td>
</tr>
<tr>
<td></td>
<td>REVASCAT</td>
<td>improvement mRS at 90 d</td>
</tr>
<tr>
<td></td>
<td>EXTEND-IA</td>
<td>Median Reperfusion at 24 hours</td>
</tr>
<tr>
<td></td>
<td>REVASCAT</td>
<td>improvement mRS at 90 d</td>
</tr>
<tr>
<td></td>
<td>EXTEND-IA</td>
<td>Median Reperfusion at 24 hours</td>
</tr>
<tr>
<td></td>
<td>REVASCAT</td>
<td>improvement mRS at 90 d</td>
</tr>
<tr>
<td></td>
<td>EXTEND-IA</td>
<td>Median Reperfusion at 24 hours</td>
</tr>
<tr>
<td></td>
<td>REVASCAT</td>
<td>improvement mRS at 90 d</td>
</tr>
<tr>
<td></td>
<td>EXTEND-IA</td>
<td>Median Reperfusion at 24 hours</td>
</tr>
<tr>
<td></td>
<td>REVASCAT</td>
<td>improvement mRS at 90 d</td>
</tr>
<tr>
<td></td>
<td>EXTEND-IA</td>
<td>Median Reperfusion at 24 hours</td>
</tr>
<tr>
<td></td>
<td>REVASCAT</td>
<td>improvement mRS at 90 d</td>
</tr>
<tr>
<td></td>
<td>EXTEND-IA</td>
<td>Median Reperfusion at 24 hours</td>
</tr>
</tbody>
</table>

* adjusted odds ratio, 95% Confidence Intervals (CI)
† adjusted difference, 95% CI
‡ relative risk, 99% CI
§ adjusted rate ratio, 95% CI
ll odds ratio, 95% CI
** relative risk, 95% CI
† †  adjusted risk ratio, 95% CI
Table Abbreviations (Tables 2-4)

ASPECTS  Alberta Stroke Program Early CT score; CT computed tomography; CTA computed tomography angiography; d days; EC extra-cranial; ESCAPE  Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion with Emphasis on Minimizing CT to Recanalization Times; EXTEND-IA Extending the Time for Thrombolysis in Emergency Neurological Deficits- Intra-Arterial; hrs hours; IA intra-arterial; IAT intra-arterial therapy; ICA internal carotid artery; IMS III Interventional Management of Stroke Trial III; IQR interquartile range; IV intravenous; MCA middle cerebral artery; min minutes; mos months; MR magnetic resonance; MR CLEAN The Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke; MR RESCUE MR and Recanalization of Stroke Clots Using Embolectomy; ICH intracerebral hemorrhage; mRS modified Rankin scale; N number; NIHSS National Institutes of Health Stroke Scale; OR odds ratio; rtPA recombinant tissue plasminogen activator; SD standard deviation; SWIFT PRME Solitaire FR with the Intention for Thrombectomy as Primary Endovascular Treatment of Acute Ischemic Stroke; T terminus (of the internal carotid artery); TICI thrombolysis in cerebral infarction; yrs years


on behalf of the American Heart Association Stroke Council

Stroke. published online June 29, 2015;

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://stroke.ahajournals.org/content/early/2015/06/26/STR.0000000000000074

Data Supplement (unedited) at:

http://stroke.ahajournals.org/content/suppl/2017/07/10/STR.0000000000000074.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/
血管内治療に関するガイドライン
—2013年版ガイドラインの集中的アップデート—

2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment

A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.

Endorsed by the American Association of Neurological Surgeons (AANS); Congress of Neurological Surgeons (CNS); AANS/CNS Cerebrovascular Section; American Society of Neuroradiology; and Society of Vascular and Interventional Neurology

William J. Powers, MD, FAHA, Chair; Colin P. Derdeyn, MD, FAHA, Vice Chair; José Biller, MD, FAHA; Christopher S. Coffey, PhD; Brian L. Hob, MD, FAHA; Edward C. Jauch, MD, MS, FAHA; Karen C. Johnston, MD, MSc; S. Claiborne Johnston, MD, PhD, FAHA; Alexander A. Khalessi, MD, MS, FAHA; Chelsea S. Kidwell, MD, FAHA; James F. Meschia, MD, FAHA; Bruce Ovbiagele, MD, MSc, MAS, FAHA; Dileep R. Yavagal, MD, MBBS; on behalf of the American Heart Association Stroke Council

Stroke. 2015;46:3024-3039. DOI: 10.1161/STR.0000000000000074.
例（全体の5.5%）にあたり、中壊した4試験も完了した無作為試験として扱われている。これを5件の試験は全て前方循環系（内頭動脈、中大脳動脈）に限定され、プロトコールで設定された対象症例は、年齢18～80歳、IV-PA療法必要・不必要、NIHSS＞2から無制限、発症前の機能mRS 0-1から無制限、ASPECTS ≥6から無制限、発症から動脈穿刺まで6〜8時間であった。実際に5件の試験に登録された症例は、平均年齢66〜71歳、IV-PA療法83.7〜95%、NIHSS（中央値）13～17、ASPECTS（中央値）7〜9、発症から動脈穿刺まで（中央値）210〜269分、再開通率（TICI 2b/3）59〜86%，発症から再灌流まで（中央値）248〜355分であった。

今回の急性虚血性脳卒中の血管内治療に関する推奨（表2）は、上記の臨床試験の結果をふまえて作成されているが、第2項の満たすべき基準のうち、発症前機能についてはMR CLEAN試験には項目が無く、他の3試験でmRS 0-1であったためmRS 0-1が記載されているが、これ以下の発症前機能についてはデータが乏しいとしている。NIHSSについてもNIHSS ≥6が記載されているが、本文ではNIHSS <6はデータが不充分としている。ASPECTについても≥6を採用しているが、<6の症例の効果は不明としている。発症後6時間以内の頭部CTに对比して、5件のうちMR CLEAN試験を含む3件で発症後6時間以内と規定していたため採択され、6時間以上での効果は不明である。これらデータ不足や効果不明で基準を満たさない症例、あるいは後方循環（椎骨脳底動脈）系のように試験の対象でなかった症例の取り扱いは、各国あるいは各学会により異なることが予想される。他の推奨についても、根幹となる議論は英文ガイドラインに記載されているため参照いただきたい。本ガイドラインの画像診断についての検討はされており推奨も限定的である（表3）。全ての試験において、血管造影にはCTA、MRA、あるいはDSAが用いられたが、脳灌流測定の報告は2試験に限られており、有益性は不明としている。血管内治療の普及に伴い、米国では血管内治療を迅速に行える包括的脳卒中センターニの確立と、スムーズな患者移送システムの確立が必要とされている（表4）。

（文責：柳原武彦）

<table>
<thead>
<tr>
<th>表1A 患者診療における臨床的、介入、治療法または診断検査に対する推奨のクラス*（強さ）</th>
<th>有効性＞＞＞リスク</th>
</tr>
</thead>
<tbody>
<tr>
<td>クラスI（強い） 推奨において提案される言葉囲込：</td>
<td>有効性＞＞＞リスク</td>
</tr>
<tr>
<td>・推奨される</td>
<td>有効性＞＞＞リスク</td>
</tr>
<tr>
<td>・適応となる／有用である／有効である／有益である</td>
<td>有効性＞＞＞リスク</td>
</tr>
<tr>
<td>・実施すべきである／投与すべきである／その他</td>
<td>有効性＞＞＞リスク</td>
</tr>
<tr>
<td>・比較効果の言葉囲込：</td>
<td>有効性＞＞＞リスク</td>
</tr>
<tr>
<td>・治療法Aは治療法Bに優先して推奨される／治療法Bに優先して適応となる</td>
<td>有効性＞＞＞リスク</td>
</tr>
<tr>
<td>・治療法Bよりも治療法Aを選択すべきである</td>
<td>有効性＞＞＞リスク</td>
</tr>
<tr>
<td>クラスIIa（中程度） 推奨において提案される言葉囲込：</td>
<td>有効性＞＞＞リスク</td>
</tr>
<tr>
<td>・妥当である</td>
<td>有効性＞＞＞リスク</td>
</tr>
<tr>
<td>・用ることとなる／有用である／有効である／有益である</td>
<td>有効性＞＞＞リスク</td>
</tr>
<tr>
<td>・比較効果の言葉囲込：</td>
<td>有効性＞＞＞リスク</td>
</tr>
<tr>
<td>・治療法Aはおそらく治療法Bに優先して推奨される／おそらく治療法Bに優先して適応となる</td>
<td>有効性＞＞＞リスク</td>
</tr>
<tr>
<td>・治療法Bよりも治療法Aを選択するのが妥当である</td>
<td>有効性＞＞＞リスク</td>
</tr>
<tr>
<td>クラスIIb（弱い） 推奨において提案される言葉囲込：</td>
<td>有効性・リスク</td>
</tr>
<tr>
<td>・妥当かもしれない／妥当な場合がある</td>
<td>有効性・リスク</td>
</tr>
<tr>
<td>・考慮される場合もある／考慮してもよろかもしれない</td>
<td>有効性・リスク</td>
</tr>
<tr>
<td>・有用性／有効性は不明である／明らかでない／確立されていない</td>
<td>有効性・リスク</td>
</tr>
<tr>
<td>クラスIIc-有益性なし（中程度）【一般的に、エビデンスレベルAまたはBのみに使用】推奨において提案される言葉囲込：</td>
<td>有効性・リスク</td>
</tr>
<tr>
<td>・推奨されない</td>
<td>有効性・リスク</td>
</tr>
<tr>
<td>・適応となる／有用でない／有効でない／有益でない</td>
<td>有効性・リスク</td>
</tr>
<tr>
<td>・実施すべきでない／投与すべきでない／その他</td>
<td>有効性・リスク</td>
</tr>
<tr>
<td>クラスIII：有害（弱い） 推奨において提案される言葉囲込：</td>
<td>リスク＞有効性</td>
</tr>
<tr>
<td>・潜在的に有害である</td>
<td>リスク＞有効性</td>
</tr>
<tr>
<td>・有害を及ぼす</td>
<td>リスク＞有効性</td>
</tr>
<tr>
<td>・過剰を死に至ら／罹患率を伴う</td>
<td>リスク＞有効性</td>
</tr>
<tr>
<td>・実施すべきでない／投与すべきでない／その他</td>
<td>リスク＞有効性</td>
</tr>
</tbody>
</table>

*介入の転換または結核は特定されるべきである（臨床的療の改善または診断基準の向上または予後情報の増加）。
1比較効果の推奨（クラスIおよびIIaはエビデンスレベルAおよびBのみに）、その試験において評価されている治療法または診断の直接比较が行われていることが必要である。
表 1B 患者診療における臨床戦略、介入、治療または診断検査に対するエビデンスレベル（質）

レベルA
- 複数の無作為比較試験で得られた質の高いエビデンス
- 質の高い無作為比較試験のメタ解析
- 質の高い試験結果により裏付けられた1つまたは複数の無作為比較試験

レベルB（非無作為試験）
- 1つまたは複数の無作為比較試験で得られた中等度の質のエビデンス
- 中等度の質の無作為比較試験のメタ解析

レベルB-NR（非無作為試験）
- 適切にデザインされ、適切に実施された1つまたは複数の非無作為試験、観察試験または登録試験で得られた中等度の質のエビデンス
- このような試験のメタ解析

レベルC
- デザインまたは実施内容に限界のある無作為または非無作為観察試験または登録試験
- このような試験のメタ解析
- ヒト実験者を対象とした生理学的研究または物理的研究

レベルE
エビデンスが不十分、あいまい、または相矛盾する場合の臨床経験に基づく専門家の意見

1 標準化され、広く使用されており、できるだけ妥当性が確認されているエビデンスグレード分類法を適用することや、系統的レビューについてはエビデンスレビュー委員会を設置することも含めて、質の評価方法は進歩しています。

表 2 血管内治療に関する推奨

推 奨 | エビデンスのクラスとレベル
---|---
1. rt-PA 静脈内投与の適応となる患者には、血管内治療が考慮されている場合でもrt-PA を静脈内投与すべきである（2013 年ガイドラインから変更） | クラス I：エビデンスレベル A
2. 以下の基準をすべて満たす場合には、ステントリトリバーやを用いた血管内治療を実施すべきである（新たな推奨）。
   a. 脳卒中発症前のmRS スコア 0～1
   b. 急性脳血管障害に対する専門医のガイドラインを小脳疾患後 4.5 時間以内にrt-PA が静脈内投与されている
   c. 内膜弾性または急性脳動脈近位部（M1）に脳卒中原因となる閉塞がみられる
   d. 年齢 ≥ 18 歳
   e. NIHSS スコア ≥ 6
   f. ASPECTS ≥ 6
   g. 発症後 6 時間以内に治療が開始可能（脳血管障害） | クラス I：エビデンスレベル B-R
3. rt-PA の静脈内投与と同様、発症から血管内治療による再灌流までの時間を短縮すると良好な臨床転帰が得られる。効果を確保するため、できるだけ早後に、かつ脳卒中発症後 6 時間以内に TICI グレード 2b/3 まで再灌流をもとめられる（2013 年ガイドラインから変更） | クラス Ia：エビデンスレベル C
4. 内膜弾性または急性脳動脈近位部（M1）に脳卒中原因となる閉塞を有する急性脳血管障害患者の発症後 6 時間以内に治療を開始する場合、血管内治療の効果は確実ではない。無作為試験のデータがさらに必要（新たな推奨） | クラス Ia：エビデンスレベル C
5. 前方循環系閉塞を有し、st-PA の静脈内投与が禁忌の患者のうち、慎重に選択した患者では、脳卒中発症後 6 時間以内にすむべきでさえステントリトリバーによる血管内治療は妥当である。禁忌と時間が内であるか否か（脳卒中の既往、重篤な頭部神経学的異常症候群の既往、頭部外傷の既往、急性脳障害または急性脳障害投与中）などにかかわらず、ステントリトリバーによる血管内治療の臨床的有効性を判断するには、現時点ではデータが十分でないと新たな推奨 | クラス Ia：エビデンスレベル C
6. 急性脳血管障害発症、発症後 6 時間以内に治療が開始可能（脳血管障害、脳動脈閉塞症の M2 または M3、前大脳動脈、検索動脈、脳動脈または後大脳動脈に脳卒中の原因となる閉塞を有する患者のうち、慎重に選択した患者）では、有益性は確実ではないが、ステントリトリバーによる血管内治療が妥当かもしれない（新たな推奨）。 | クラス Ia：エビデンスレベル C
7. 急性脳血管障害発症、脳動脈閉塞の閉塞を有し、発症後 6 時間以内に治療が開始可能（脳血管障害、脳動脈閉塞症の M2 または M3、前大脳動脈、検索動脈、脳動脈または後大脳動脈に脳卒中の原因となる閉塞を有する患者のうち、基幹動脈の閉塞を有し、発症後 6 時間以内に治療が開始可能（脳血管障害））の 18 歳未満の一部の患者では、ステントリトリバーによる血管内治療が妥当かもしれないが、この研究集団では有益性が確認されていない（新たな推奨）。 | クラス Ia：エビデンスレベル C
8. 急性脳血管障害発症、脳動脈閉塞の閉塞を有し、発症後 6 時間以内に治療が開始可能（脳血管障害、脳動脈閉塞症の M2 または M3、前大脳動脈、検索動脈、脳動脈または後大脳動脈に脳卒中の原因となる閉塞を有する患者）では、有益性は確実ではないが、ステントリトリバーによる血管内治療は妥当かもしれない。無作為試験のデータがさらに必要（新たな推奨）。 | クラス Ia：エビデンスレベル B-R
9. 血管内治療を実施する前に、臨床的効果を評価する目的でrt-PA 静脈内投与後に患者を観察することは、有益な治療結果を得るためには必要でなく、推奨される（新たな推奨）。 | クラス I：エビデンスレベル B-R
10. ステントリトリバーの使用を MERCI デバイスより優先すべきである。 | クラス I：エビデンスレベル A
    ステントリトリバー以外の機械的血栓除去デバイスの使用が妥当な場合もある（新たな推奨）。 | クラス Ia：エビデンスレベル B-NR

（次ページへ続く）
表2 血管内治療に関する推奨（前ページより続く）

<table>
<thead>
<tr>
<th>推奨</th>
<th>エビデンスのクラスとレベル</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>クラスⅠa：エビデンスレベルC</td>
</tr>
<tr>
<td>2.</td>
<td>クラスⅠb：エビデンスレベルB-C</td>
</tr>
<tr>
<td>3.</td>
<td>クラスⅠc：エビデンスレベルB-C</td>
</tr>
</tbody>
</table>

表3 画像診断に関する推奨

<table>
<thead>
<tr>
<th>推奨</th>
<th>エビデンスのクラスとレベル</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>クラスⅠa：エビデンスレベルA</td>
</tr>
<tr>
<td>2.</td>
<td>クラスⅠb：エビデンスレベルC</td>
</tr>
</tbody>
</table>

表4 脳卒中の治療体制に関する推奨

<table>
<thead>
<tr>
<th>推奨</th>
<th>エビデンスのクラスとレベル</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>クラスⅠa：エビデンスレベルA</td>
</tr>
<tr>
<td>2.</td>
<td>クラスⅠb：エビデンスレベルB-C</td>
</tr>
</tbody>
</table>

Vol. 10, No. 5